These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 23883125)

  • 1. Recent advances in porous silicon technology for drug delivery.
    Barnes TJ; Jarvis KL; Prestidge CA
    Ther Deliv; 2013 Jul; 4(7):811-23. PubMed ID: 23883125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surface chemistry of porous silicon and implications for drug encapsulation and delivery applications.
    Jarvis KL; Barnes TJ; Prestidge CA
    Adv Colloid Interface Sci; 2012 Jul; 175():25-38. PubMed ID: 22521238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of porous silicon nanocarriers for parenteral peptide delivery.
    Kovalainen M; Mönkäre J; Kaasalainen M; Riikonen J; Lehto VP; Salonen J; Herzig KH; Järvinen K
    Mol Pharm; 2013 Jan; 10(1):353-9. PubMed ID: 23186283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of surface chemistry of porous silicon microparticles on glucagon-like peptide-1 (GLP-1) loading, release and biological activity.
    Huotari A; Xu W; Mönkäre J; Kovalainen M; Herzig KH; Lehto VP; Järvinen K
    Int J Pharm; 2013 Sep; 454(1):67-73. PubMed ID: 23834832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ¹⁸F-labeled modified porous silicon particles for investigation of drug delivery carrier distribution in vivo with positron emission tomography.
    Sarparanta M; Mäkilä E; Heikkilä T; Salonen J; Kukk E; Lehto VP; Santos HA; Hirvonen J; Airaksinen AJ
    Mol Pharm; 2011 Oct; 8(5):1799-806. PubMed ID: 21875120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled drug delivery from composites of nanostructured porous silicon and poly(L-lactide).
    McInnes SJ; Irani Y; Williams KA; Voelcker NH
    Nanomedicine (Lond); 2012 Jul; 7(7):995-1016. PubMed ID: 22394185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surface chemistry and pore size affect carrier properties of mesoporous silicon microparticles.
    Limnell T; Riikonen J; Salonen J; Kaukonen AM; Laitinen L; Hirvonen J; Lehto VP
    Int J Pharm; 2007 Oct; 343(1-2):141-7. PubMed ID: 17600644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanostructured porous silicon-polymer-based hybrids: from biosensing to drug delivery.
    Bonanno LM; Segal E
    Nanomedicine (Lond); 2011 Dec; 6(10):1755-70. PubMed ID: 22122584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surface engineering of porous silicon microparticles for intravitreal sustained delivery of rapamycin.
    Nieto A; Hou H; Moon SW; Sailor MJ; Freeman WR; Cheng L
    Invest Ophthalmol Vis Sci; 2015 Jan; 56(2):1070-80. PubMed ID: 25613937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats.
    Bimbo LM; Sarparanta M; Santos HA; Airaksinen AJ; Mäkilä E; Laaksonen T; Peltonen L; Lehto VP; Hirvonen J; Salonen J
    ACS Nano; 2010 Jun; 4(6):3023-32. PubMed ID: 20509673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Porous silicon nanomaterials: recent advances in surface engineering for controlled drug-delivery applications.
    Zhang DX; Esser L; Vasani RB; Thissen H; Voelcker NH
    Nanomedicine (Lond); 2019 Dec; 14(24):3213-3230. PubMed ID: 31855121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesoporous silicon in drug delivery applications.
    Salonen J; Kaukonen AM; Hirvonen J; Lehto VP
    J Pharm Sci; 2008 Feb; 97(2):632-53. PubMed ID: 17546667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multifunctional porous silicon for therapeutic drug delivery and imaging.
    Santos HA; Bimbo LM; Lehto VP; Airaksinen AJ; Salonen J; Hirvonen J
    Curr Drug Discov Technol; 2011 Sep; 8(3):228-49. PubMed ID: 21291407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Porous silicon for drug delivery applications and theranostics: recent advances, critical review and perspectives.
    Kumeria T; McInnes SJP; Maher S; Santos A
    Expert Opin Drug Deliv; 2017 Dec; 14(12):1407-1422. PubMed ID: 28398108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering porous silicon nanostructures as tunable carriers for mitoxantrone dihydrochloride.
    Tzur-Balter A; Gilert A; Massad-Ivanir N; Segal E
    Acta Biomater; 2013 Apr; 9(4):6208-17. PubMed ID: 23274152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro cytotoxicity of porous silicon microparticles: effect of the particle concentration, surface chemistry and size.
    Santos HA; Riikonen J; Salonen J; Mäkilä E; Heikkilä T; Laaksonen T; Peltonen L; Lehto VP; Hirvonen J
    Acta Biomater; 2010 Jul; 6(7):2721-31. PubMed ID: 20036766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel pressed porous silicon-polycaprolactone composite as a dual-purpose implant for the delivery of cells and drugs to the eye.
    Irani YD; Tian Y; Wang M; Klebe S; McInnes SJ; Voelcker NH; Coffer JL; Williams KA
    Exp Eye Res; 2015 Oct; 139():123-31. PubMed ID: 26277579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro assessment of biopolymer-modified porous silicon microparticles for wound healing applications.
    Mori M; Almeida PV; Cola M; Anselmi G; Mäkilä E; Correia A; Salonen J; Hirvonen J; Caramella C; Santos HA
    Eur J Pharm Biopharm; 2014 Nov; 88(3):635-42. PubMed ID: 25305585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxidized mesoporous silicon microparticles for improved oral delivery of poorly soluble drugs.
    Wang F; Hui H; Barnes TJ; Barnett C; Prestidge CA
    Mol Pharm; 2010 Feb; 7(1):227-36. PubMed ID: 19874003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aqueous and thermal oxidation of porous silicon microparticles: implications on molecular interactions.
    Jarvis KL; Barnes TJ; Prestidge CA
    Langmuir; 2008 Dec; 24(24):14222-6. PubMed ID: 19053643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.